Reneuron Group (RENE)

 

RENE Share PerformanceMore

52 week high3.7125 25/05/16
52 week low2.0000 23/05/17
52 week change -1.2500 (-38.46%)
4 week volume52,807,529 28/04/17

Media for (RENE)

Presenter: Michael Hunt, CEO
04/02/2015

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

ReNeuron presents positive exosome data

ReNeuron Group will be presenting new positive pre-clinical data relating to its ExoPr0 CTX cell-derived exosome therapy...

Presents positive exosome data at major conference

RNS Number: 4700F ReNeuron Group plc 18 May 2017 AIM: RENE 18 May 2017 ReNeuron Group plc ReNeuron presents positive pre-clinical data with its ExoPr0 exosome therapy candidate at major scientific conference Data show that ExoPr0 can cross the blood brain barrier and can potentially target multiple diseases via local or systemic administration ReNeur...

ReNeuron awarded £1.8m grant from Innovate UK

ReNeuron Group has been awarded a 1.8m grant from Innovate UK to further advance its next generation commercial ce...

Awarded major UK cell therapy manufacturing grant

RNS Number: 7818E ReNeuron Group plc 11 May 2017 AIM: RENE 11 May 2017 ReNeuron Group plc ReNeuron awarded major UK cell therapy manufacturing grant ReNeuron Group plc (the "Company") (AIM: RENE), a leading UK-based stem cell therapy development company, is pleased to announce that it has been awarded a 1.8 million grant from Innovate U...

Presents new exosome data at major conference

RNS Number: 2515E ReNeuron Group plc 05 May 2017 AIM: RENE 5 May 2017 ReNeuron Group plc ReNeuron presents new data with its exosome therapy programme at major scientific conference ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it will today b...

ReNeuron updates on ophthalmology programmes

ReNeuron Group has reported very significant positive developments with its retinal disease programme.

ReNeuron updates on clinical strategy in stroke disability

ReNeuron Group says it expects to be able to begin a Phase III study with its CTX cell therapy candidate in stroke disability...

Update on clinical strategy in stroke disability

RNS Number: 9274C ReNeuron Group plc 21 April 2017 AIM: RENE 21 April 2017 ReNeuron Group plc ReNeuron advances global clinical development strategy with cell therapy candidate for stroke disability ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide an update...

Fundamental DataMore

EPS-0.4
Dividend yield0 %

Equity Research (RENE)

edison investment research
ReNeuron Group plc
02/05/2017
ReNeuron continues to prepare for its Phase III chronic stroke study (due to start in H217) and has indicated that it is making progress with the US/EU regulatory authorities. It intends to submit an...
edison investment research
ReNeuron Group plc
23/03/2017
ReNeuron reported in December 2016 positive Phase II trial data for its CTX cells in chronic stroke patients, despite not meeting the three-month time frame of a two-point improvement in its primary...
edison investment research
ReNeuron Group plc
07/12/2016
ReNeuron has presented positive Phase II trial data for its CTX cells in chronic stroke patients. Reported data included 15 out of 21 patients having a clinically relevant and sustained response on...

Latest discussion posts More

  • Re: Glialign

    Consultancy services for who, and from his employer's premesis??
    23-May-2017
    grizzlyb
  • Have we hit bottom yet ?

    With the eye of faith, the five yearly chart with weekly bars would appear to say so - hmm.
    23-May-2017
    loper
  • Re: Glialign

    I'd assume he is just offering consultancy services through a limited company for tax purposes
    23-May-2017
    greenroma

Users' HoldingsMore

Users who hold Reneuron Group also hold..
LLOYDS GRP.16%
BP12%
ROCKHOPPER11%
BARCLAYS11%
ROYAL BANK SCOT11%

Codes & Symbols

ISINGB00B0DZML60
SymbolsRENE, LSE:RENE, RENE.L, RENE:LN, LON:RENE, XLON:RENE